SHANGHAI, April 10 (Reuters) - Amgen's lung cancer drug tarlatamab has won approval from China's National Medical Products Administration, its development and commercialisation partner BeOne Medicines ...
The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.
China approved Amgen’s tarlatamab for previously treated small cell lung cancer, expanding access to the bispecific immunotherapy. Amgen’s bispecific T-cell engager tarlatamab received regulatory ...
Zacks Investment Research on MSN
Why Amgen (AMGN) is poised to beat earnings estimates again
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Amgen (AMGN), which belongs to the Zacks Medical ...
A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
Viridian Therapeutics (VRDN) remains a 'Sell' as both lead TED assets underperform versus Amgen’s Tepezza, with limited ...
Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...
With another year of double-digit revenue growth in the books, Amgen’s longtime helmsman Robert Bradway continues to sit ...
The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts ...
The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall ...
Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results